You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Santhera submits marketing authorisation application for vamorolone

Santhera has announced that the company has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for vamorolone. The therapy is used for the treatment of Duchenne muscular dystrophy (DMD).